Table 5.
Univariate analysis in terms of disease-free survival (DFS) and overall survival (OS). The Cox regression analysis was performed for the five genes considered either singularly or included in a five-gene signature. Hazard ratios and confidence intervals were calculated using the survival R/Bioconductor package.
| Variable | Patients Number | HR | 95% C.I. | p-Value |
|---|---|---|---|---|
| DFS (12 months) | ||||
| CCL2 expression | High (n = 44) Low (n = 74) |
1 0.54 |
0.33–0.88 | 0.012 |
| CXCL2 expression | High (n = 40) Low (n = 78) |
1 0.42 |
0.26–0.68 | <0.01 |
| CXCL8 expression | High (n = 42) Low (n = 76) |
1 0.58 |
0.36–0.94 | 0.029 |
| SPP1 expression | High (n = 81) Low (n = 37) |
1 0.56 |
0.32–0.96 | 0.034 |
| TGFB1 expression | High (n = 37) Low (n = 81) |
1 0.61 |
0.37–1 | 0.049 |
| Five gene signature expression | High (n = 78) Low (n = 40) |
1 0.56 |
0.33–0.95 | 0.03 |
| OS (24 months) | ||||
| CCL2 expression | High (n = 103) Low (n = 61) |
1 0.63 |
0.43–0.94 | 0.022 |
| CXCL2 expression | High (n = 60) Low (n = 104) |
1 0.56 |
0.38–0.81 | 0.002 |
| CXCL8 expression | High (n = 90) Low (n = 74) |
1 0.76 |
0.52–1.1 | 0.153 |
| SPP1 expression | High (n = 128) Low (n = 36) |
1 0.62 |
0.39–1 | 0.052 |
| TGFB1 expression | High (n = 51) Low (n = 113) |
1 0.63 |
0.43–0.93 | 0.021 |
| Five gene signature expression | High (n = 111) Low (n = 53) |
1 0.64 |
0.42–0.96 | 0.03 |